Clinical trial
An Open-label, Dose-escalation Study With Extension to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO4987655, a MEK Inhibitor, Administered Orally as Monotherapy in Patients With Advanced Tumors
NCT00817518 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Dose-escalation Study With Extension to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO4987655, a MEK Inhibitor, Administered Orally as Monotherapy in Patients With Advanced Tumors
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2009
- Completion date
- December 31, 2014
- Enrollment
- 145 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.